In a multicenter series of randomized prospective doubleblind controlled studies, ritodrine hydrochloride was compared with either ethanol or placebo in treatment of idiopathic preterm labor. When compared with controls, there was, among offspring of ritodrine-treated mothers, a significantly reduced incidence of neonatal death and respiratory distress syndrome (P<.05 in both comparisons) and a significantly higher proportion of infants achieving 36 weeks' gestation (P<.05) or birth weight greater than 2500 g (P<.05). There was also a significant improvement in gestational age at delivery (P<.05) and in the number of days gained in utero (P<.001) among ritodrine-treated patients as compared with controls. These results, coupled with a finding of generally acceptable side effects, have contributed to ritodrine's becoming the first drug approved for the treatment of preterm labor in the United States.
|Original language||English (US)|
|Number of pages||6|
|Journal||Obstetrics and gynecology|
|Publication status||Published - Jul 1980|
ASJC Scopus subject areas
- Obstetrics and Gynecology